Long-term treatment of rheumatoid arthritis with adalimumab

Giuseppe Murdaca, Francesca Spanò, Francesco PuppoDepartment of Internal Medicine, Clinical Immunology Unit, University of Genoa, Genoa, ItalyAbstract: Rheumatoid arthritis (RA) is a chronic inflammatory disease that is associated with joint damage and progressive disability, an increased...

Full description

Bibliographic Details
Main Authors: Murdaca G, Spano F, Puppo F
Format: Article
Language:English
Published: Dove Medical Press 2013-05-01
Series:Open Access Rheumatology : Research and Reviews
Online Access:http://www.dovepress.com/long-term-treatment-of-rheumatoid-arthritis-with-adalimumab-a13001
id doaj-15696d463d87450fb6f77dc0f7913dd6
record_format Article
spelling doaj-15696d463d87450fb6f77dc0f7913dd62020-11-24T22:49:19ZengDove Medical PressOpen Access Rheumatology : Research and Reviews1179-156X2013-05-012013default4349Long-term treatment of rheumatoid arthritis with adalimumabMurdaca GSpano FPuppo FGiuseppe Murdaca, Francesca Spanò, Francesco PuppoDepartment of Internal Medicine, Clinical Immunology Unit, University of Genoa, Genoa, ItalyAbstract: Rheumatoid arthritis (RA) is a chronic inflammatory disease that is associated with joint damage and progressive disability, an increased risk of morbidity related to comorbid conditions and substantial socioeconomic costs. Tumor necrosis factor-alpha (TNF-α) is a proinflammatory cytokine known to have a central role in the initial host response to infection and in the pathogenesis of various immune-mediated diseases, such as RA, ankylosing spondylitis, psoriasis and/or psoriatic arthritis, Crohn’s disease, and systemic lupus erythematosus. Five TNF-α inhibitors are available for the clinical use: infliximab; adalimumab; etanercept; golimumab; and certolizumab pegol. Infliximab is a chimeric human/murine IgG1 monoclonal antibody (mAb); adalimumab, and golimumab are human mAbs; certolizumab pegol is composed of the fragment antigen-binding anti-binding domain of a humanized anti-TNF-α mAb, combined with polyethylene glycol to increase its half-life in the body; etanercept is a fusion protein that acts as a “decoy receptor” for TNF-α. In this paper, we will briefly review the current data on efficacy and safety of adalimumab in patients with RA, its potential beneficial effects upon comorbid conditions, such as endothelial dysfunction and accelerated atherosclerosis in RA, and the immunogenicity.Keywords: adalimumab, efficacy, safety, rheumatoid arthritis, VEGF, immunogenicity, infectionshttp://www.dovepress.com/long-term-treatment-of-rheumatoid-arthritis-with-adalimumab-a13001
collection DOAJ
language English
format Article
sources DOAJ
author Murdaca G
Spano F
Puppo F
spellingShingle Murdaca G
Spano F
Puppo F
Long-term treatment of rheumatoid arthritis with adalimumab
Open Access Rheumatology : Research and Reviews
author_facet Murdaca G
Spano F
Puppo F
author_sort Murdaca G
title Long-term treatment of rheumatoid arthritis with adalimumab
title_short Long-term treatment of rheumatoid arthritis with adalimumab
title_full Long-term treatment of rheumatoid arthritis with adalimumab
title_fullStr Long-term treatment of rheumatoid arthritis with adalimumab
title_full_unstemmed Long-term treatment of rheumatoid arthritis with adalimumab
title_sort long-term treatment of rheumatoid arthritis with adalimumab
publisher Dove Medical Press
series Open Access Rheumatology : Research and Reviews
issn 1179-156X
publishDate 2013-05-01
description Giuseppe Murdaca, Francesca Spanò, Francesco PuppoDepartment of Internal Medicine, Clinical Immunology Unit, University of Genoa, Genoa, ItalyAbstract: Rheumatoid arthritis (RA) is a chronic inflammatory disease that is associated with joint damage and progressive disability, an increased risk of morbidity related to comorbid conditions and substantial socioeconomic costs. Tumor necrosis factor-alpha (TNF-α) is a proinflammatory cytokine known to have a central role in the initial host response to infection and in the pathogenesis of various immune-mediated diseases, such as RA, ankylosing spondylitis, psoriasis and/or psoriatic arthritis, Crohn’s disease, and systemic lupus erythematosus. Five TNF-α inhibitors are available for the clinical use: infliximab; adalimumab; etanercept; golimumab; and certolizumab pegol. Infliximab is a chimeric human/murine IgG1 monoclonal antibody (mAb); adalimumab, and golimumab are human mAbs; certolizumab pegol is composed of the fragment antigen-binding anti-binding domain of a humanized anti-TNF-α mAb, combined with polyethylene glycol to increase its half-life in the body; etanercept is a fusion protein that acts as a “decoy receptor” for TNF-α. In this paper, we will briefly review the current data on efficacy and safety of adalimumab in patients with RA, its potential beneficial effects upon comorbid conditions, such as endothelial dysfunction and accelerated atherosclerosis in RA, and the immunogenicity.Keywords: adalimumab, efficacy, safety, rheumatoid arthritis, VEGF, immunogenicity, infections
url http://www.dovepress.com/long-term-treatment-of-rheumatoid-arthritis-with-adalimumab-a13001
work_keys_str_mv AT murdacag longtermtreatmentofrheumatoidarthritiswithadalimumab
AT spanof longtermtreatmentofrheumatoidarthritiswithadalimumab
AT puppof longtermtreatmentofrheumatoidarthritiswithadalimumab
_version_ 1725676307992281088